PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced a peer-review publication which contains results of skin penetration…Read More
Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP103 lidocaine topical system 54 a Triple Strength Formulation of ZTlido in Treatment of Musculoskeletal Pain Disorders
